Evolent Health stock gained 7.81 percent on October 7

Published on 10/08/2026 at 04:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evolent Health stock posted Q2 2026 revenue of USD 652.5 million, up 46.9 percent year over year. MarketBeat lists 16 analysts and a USD 5.96 average target.

EVH, US30050B1017, Illustration mit AI erstellt.

Evolent Health stock (ISIN US30050B1017) was last at USD 4.14 on the NYSE on October 7, 2026 at 4:00 p.m. ET, up 7.81 percent from the prior close of USD 3.84. The price move stands on its own in the market record, while the latest operating figures give investors a separate measure of the company.

Q2 revenue reached USD 652.52 million

Evolent Health reported USD 652.52 million in second-quarter 2026 revenue, an increase of 46.9 percent from the same quarter a year earlier, according to Yahoo Finance on September 16, 2026. The report said the result exceeded analyst expectations by 9.4 percent and that the company also beat adjusted earnings-per-share expectations.

The quarter still carried a profitability strain. Evolent Health's consolidated net loss was USD 28.36 million in Q2 2026, while diluted GAAP EPS was negative USD 0.25 and the operating margin was negative 1 percent for the period.

Consensus target sits above the stock

MarketBeat reported on October 7, 2026 that 16 analysts carried a Moderate Buy consensus, with 11 buys, four holds and one sell. The average 12-month price target was USD 5.96, which is 44.0 percent above the October 7 price of USD 4.14.

Recent individual actions were mixed. MarketBeat said Citigroup had upgraded Evolent Health to Buy while cutting its target from USD 6.75 to USD 6.00 on August 10, 2026, and Truist Financial had reduced its target from USD 7.00 to USD 6.00 while keeping a Hold rating on August 12, 2026.

Stock remains below its yearly high

The October 7 price stood between the 52-week low of USD 2.10 and high of USD 8.34. At USD 4.14, the stock was 50.4 percent below that high, leaving the operating recovery and the path toward consistent profitability as the central valuation questions.

Evolent Health reported negative operating cash flow of USD 9.31 million in Q2 2026. Revenue growth therefore provides the clearest positive operating signal, while the loss, margin and cash flow figures show why the analyst target still depends on execution rather than revenue expansion alone.

NYSE price and company details

Evolent Health was last at USD 4.14 on the NYSE on October 7, 2026 at 4:00 p.m. ET. The stock's market capitalization was USD 465.7 million on that date.